Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMET12 in EGFR-positive Advanced Solid Tumors (Phase I/IIa, PK and Safety)
ChiCTR2500111540Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SMET12 in solid neoplasms, non-small cell lung cancer (NSCLC), head and neck cancer (HNC) and 3 more (6 cohorts), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Overall Survival (OS). Started Nov 2025; status: recruiting.
02
Drugs
SMET12
03
Conditions
solid neoplasmsnon-small cell lung cancer (NSCLC)head and neck cancer (HNC)Esophageal Squamous Cell Carcinoma (ESCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2500111540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111540.